IRIS
SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.177
EU - Europa 1.362
AS - Asia 1.329
SA - Sud America 414
Continente sconosciuto - Info sul continente non disponibili 105
AF - Africa 92
Totale 6.479
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.127
SG - Singapore 448
BR - Brasile 324
VN - Vietnam 275
RU - Federazione Russa 232
CN - Cina 226
IT - Italia 221
UA - Ucraina 192
SE - Svezia 141
DE - Germania 131
IE - Irlanda 123
TR - Turchia 108
HK - Hong Kong 80
FI - Finlandia 77
FR - Francia 73
DK - Danimarca 68
GB - Regno Unito 52
CI - Costa d'Avorio 40
IN - India 40
KR - Corea 38
BD - Bangladesh 29
AR - Argentina 22
CA - Canada 22
JP - Giappone 21
MA - Marocco 21
MX - Messico 20
CO - Colombia 18
IQ - Iraq 15
ZA - Sudafrica 14
NL - Olanda 13
EC - Ecuador 12
PL - Polonia 10
CL - Cile 9
ID - Indonesia 9
VE - Venezuela 9
ES - Italia 8
PY - Paraguay 7
UY - Uruguay 7
MY - Malesia 6
BE - Belgio 5
KE - Kenya 5
PE - Perù 5
PK - Pakistan 5
UZ - Uzbekistan 5
CZ - Repubblica Ceca 4
EU - Europa 4
PH - Filippine 4
SA - Arabia Saudita 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
RS - Serbia 3
SC - Seychelles 3
AT - Austria 2
AZ - Azerbaigian 2
CR - Costa Rica 2
DZ - Algeria 2
HN - Honduras 2
LT - Lituania 2
TW - Taiwan 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GT - Guatemala 1
IM - Isola di Man 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
LB - Libano 1
MM - Myanmar 1
MT - Malta 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
TH - Thailandia 1
Totale 6.378
Salva come PNG Salva come JPEG
Città #
Ashburn 612
Singapore 292
Fairfield 210
Jacksonville 210
Chandler 199
San Jose 139
Dublin 121
Wilmington 120
Dallas 118
Council Bluffs 107
Des Moines 100
Boardman 96
Woodbridge 95
New York 93
Ho Chi Minh City 81
Hong Kong 77
Seattle 77
Houston 73
Hanoi 69
The Dalles 67
Beijing 65
Cambridge 50
Centro 49
Los Angeles 49
Lawrence 47
Princeton 47
San Mateo 43
Ann Arbor 42
Lauterbourg 42
Moscow 41
Abidjan 39
Munich 34
São Paulo 29
Turin 28
Helsinki 23
San Diego 22
Chicago 21
Milan 20
London 19
Turku 19
Buffalo 18
Tokyo 15
Hefei 14
Frankfurt am Main 13
Orem 13
Porto Alegre 12
Santa Clara 12
Chennai 11
Columbus 11
Da Nang 11
Washington 11
Haiphong 10
Johannesburg 9
Pune 9
Rio de Janeiro 9
Rome 9
Curitiba 8
Denver 8
Montreal 8
Paris 8
Shanghai 8
Atlanta 7
Guayaquil 7
Montevideo 7
Warsaw 7
Amsterdam 6
Belo Horizonte 6
Brasília 6
Kilburn 6
Mumbai 6
Norwalk 6
Toronto 6
Ancona 5
Bogotá 5
Bến Tre 5
Campinas 5
Can Tho 5
Fortaleza 5
Salvador 5
Santiago 5
Stockholm 5
Tashkent 5
Thái Nguyên 5
Wuhan 5
Brooklyn 4
Brussels 4
Cagliari 4
Dhaka 4
Florence 4
Goiânia 4
Izmir 4
Manchester 4
Medellín 4
Miami 4
Miano 4
Nairobi 4
Olomouc 4
Petrópolis 4
Phoenix 4
San Francisco 4
Totale 4.106
Salva come PNG Salva come JPEG
Nome #
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 201
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 196
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 195
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 184
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 175
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 170
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 164
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 158
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 158
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 156
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 156
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 156
BRAF-mutant colorectal cancer, a different breed evolving 154
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 150
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 147
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 146
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 145
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 143
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 141
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 139
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 139
Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. 137
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 135
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 134
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 134
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 133
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 132
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 129
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 128
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 125
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 125
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 121
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 119
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 119
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 118
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 118
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 114
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 113
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 108
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. 107
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma 106
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 104
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 103
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 103
Selected news from the 2014 Genitourinary Cancers Symposium: Translating novel strategies into clinical practice 92
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 87
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. Anticancer Res. 2013 Oct;33(10):4611-7 73
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 50
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 39
Totale 6.479
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.358
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.358
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022328 0 66 10 2 1 28 15 21 24 62 42 57
2022/2023745 52 93 51 42 37 165 0 38 177 5 75 10
2023/2024408 66 8 37 42 62 114 7 12 0 7 10 43
2024/2025866 122 67 15 13 39 41 104 34 162 66 99 104
2025/20262.506 168 211 154 261 300 161 406 245 195 205 80 120
2026/2027142 86 56 0 0 0 0 0 0 0 0 0 0
Totale 6.479